drugset
drugset / Trial / NCT04172233

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

NCT04172233 ↗

Phase 1/2 Completed 96 enrolled Akeso Akeso Tiancheng, Inc · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and the preliminary efficacy of AK101，an anti-IL-12/23p40 monoclonal antibody, when administered subcutaneously in subjects with moderate-to-severe plaque psoriasis.

Timeline

Start
2018-01-09
Primary completion
2019-10-31
Completion
2019-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject EBDAROKIMAB Monoclonal antibody 45 mg Subcutaneous
Subject EBDAROKIMAB Monoclonal antibody 90 mg Subcutaneous
Subject EBDAROKIMAB Monoclonal antibody 135 mg Subcutaneous
Subject EBDAROKIMAB Monoclonal antibody 270 mg Subcutaneous

Indications

psoriasis